BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MS Patients Seek Therapy Despite FDA Warning


10/8/2012 9:07:25 AM

A controversial treatment for multiple sclerosis has been linked by U.S. health regulators to serious injuries including stroke, paralysis or even death, prompting them to issue an official warning to patients and physicians earlier this year. But California radiologist Michael Arata and other doctors are continuing to treat a condition dubbed "chronic cerebrospinal venous insufficiency," or CCSVI, on dozens of new patients, based on their conviction that it offers a better quality of life. The experimental technique, introduced three years ago, uses angioplasty balloons or stents to open up narrowed and twisted veins in the neck and chest to help blood drain from the brain. In its warning last May, the Food and Drug Administration said there is no clear evidence CCSVI exists in MS patients, and the procedure to treat it has not been shown to be safe or to help patients.

Read at Reuters

Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES